Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comparative Effectiveness Could Take A Close Look At CAM - Sebelius

This article was originally published in The Tan Sheet

Executive Summary

Comparative effectiveness research required under health care reform likely will be used to carefully test the value of complementary and alternative medicines rather than simply hold up those products as less-expensive alternatives to pharmaceuticals
Advertisement

Related Content

Group recommends targeting CER for priority populations
Group recommends targeting CER for priority populations
Group recommends targeting CER for priority populations
Health Care Reform Makes Room For Supplements In Wellness, Prevention
Health Care Reform Makes Room For Supplements In Wellness, Prevention
FTC Stakes New Territory, Joins FDA In Warning On H1N1 Claims
U.S. Comparative Effectiveness Will Not Copy U.K.’s NICE – OMB Director

Topics

Advertisement
UsernamePublicRestriction

Register

PS104011

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel